The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches

Biological Psychiatry

Volumn 50, Issue 11, 2001, Pages 884-897

  Lieberman, Jeffrey A ^a   Perkins, Diana ^a   Belger, Aysenil ^a   Chakos, Miranda ^a   Jarskog, Fred ^a   Boteva, Kalina ^a   Gilmore, John ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Course; Early intervention; Pathophysiology; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

CLINICAL FEATURE; CONFERENCE PAPER; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; HUMAN; NERVE CELL DIFFERENTIATION; NEUROPATHOLOGY; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; RELAPSE; REMISSION; SCHIZOPHRENIA; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ACUTE DISEASE; AGE OF ONSET; ANTIPSYCHOTIC AGENTS; BRAIN; CLINICAL TRIALS; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0035666578     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(01)01303-8     Document Type: Conference Paper

References (118)

1. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia
2. Altered distribution of nicotinamide-adenine dinucleotide phosphate- diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development
3. Distorted distribution of nicotinamide-adenine dinucleotide phosphate- diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development
4. London first-episode study of schizophrenia
5. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy
6. Is there a neuroanatomic basis for schizophrenia? An old question revisited
7. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging
8. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging
9. Duration of untreated psychosis predicts treatment outcome in an early psychosis program
10. Schizophrenia-neurosis
11. Advancing a neurodevelopmental origin for schizophrenia
12. Hippocampus-amygdala volumes and psychopathology in chronic schizophrenia
13. Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients
14. Midlatency evoked potentials attenuation and augmentation reflect different aspects of sensory gating
15. Defining treatment refractoriness in schizophrenia
16. Substance abuse and clozapine treatment
17. Association of prenatal and perinatal complications with subsequent bipolar disorder and schizophrenia
18. Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder
19. A prospective cohort study of genetic and perinatal influences in the etiology of schizophrenia
20. Psychopathology and the question of neurodevelopmental or neurodegenerative disorder
21. Anterior cingulate gyrus dysfunction and selective attention deficits in schizophrenia: [15O]H2O PET study during single-trial Stroop task performance
22. 1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia
23. Poor P50 suppression among schizophrenia patients and their first- degree biological relatives
24. Impaired attention, genetics, and the pathophysiology of schizophrenia
25. Oxidative stress, glutamate, and neurodegenerative disorders
26. Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series?
27. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents
28. The natural course of schizophrenia and effective maintenance drug treatment
29. Ventricular enlargement in poor-outcome schizophrenia
30. Schizophrenia as a chronic active brain process: A study of progressive brain structural change subsequent to the onset of schizophrenia
31. The timing of brain morphological changes in schizophrenia and their relationship to clinical outcome
32. A prospective follow-up study of brain morphology and cognition in first-episode schizophrenic patients: Preliminary findings
33. Causes and consequences of duration of untreated psychosis in schizophrenia
34. Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism
35. Prolonged recovery in first-episode psychosis
36. Risperidone in the treatment of first-episode psychotic patients: A double-blind multicenter study
37. High-risk research in schizophrenia: A summary of what has been learned
38. Neurobiologic antecedents of schizophrenia in children. Evidence for an inherited, congenital neurointegrative defect
39. Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: Preliminary report
40. 'Schizophrenia as a chronic active brain process ... ': Perhaps, but only in part
41. Outcome in children with fetal mild ventriculomegaly: A case series
42. Neurocognitive deficits in schizophrenia
43. Family and twin strategies as a head start in defining prodromes and endophenotypes for hypothetical early-interventions in schizophrenia
44. A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures
45. Delay to first antipsychotic medication in schizophrenia: Impact on symptomatology and clinical course of illness
46. Causes and consequences of the gender difference in age at onset of schizophrenia
47. Cognitive decline in late-life schizophrenia: A longitudinal study of geriatric chronically hospitalized patients
48. One hundred years of schizophrenia: A meta-analysis of the outcome literature
49. Untreated initial psychosis: Its relation to quality of life and symptom remission in first-episode schizophrenia
50. Lack of association between duration of untreated illness and severity of cognitive and structural brain deficits at the first episode of schizophrenia
51. Schizophrenia: Manifestations, incidence and course in different cultures. A World Health Organization ten-country study
52. Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia
53. Behavioral response to methylphenidate and treatment outcome in first episode schizophrenia
54. The early origins of schizophrenia
55. Changes in caudate volume with neuroleptic treatment
56. Magnetic resonance spectroscopy in schizophrenia: Methodological issues and findings-part II
57. Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis
58. First-episode schizophrenia with long duration of untreated psychosis. Pathways to care
59. Increased dopamine transmission in schizophrenia: Relationship to illness phases
60. Catching up on schizophrenia: Natural history and neurobiology
61. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective
62. Psychobiologic correlates of treatment response in schizophrenia
63. Qualitative assessment of brain morphology in acute and chronic schizophrenia
64. Longitudinal study of brain morphology in first episode schizophrenia
65. Delayed detection of psychosis: Causes, consequences, and effect on public health
66. Time course and biologic correlates of treatment response in first-episode schizophrenia
67. Neurochemical sensitization in the pathophysiology of schizophrenia: Deficits and dysfunction in neuronal regulation and plasticity
68. Early detection and intervention in schizophrenia
69. Duration of psychosis and outcome in first-episode schizophrenia
70. Progressive atrophy of the frontal lobes in first-episode schizophrenia: Interaction with clinical course and neuroleptic treatment
71. Proton magnetic resonance spectroscopy: An in vivo method of estimating hippocampal neuronal depletion in schizophrenia
72. Progressive brain volume changes and the clinical course of schizophrenia in men: A longitudinal magnetic resonance imaging study
73. Olanzapine versus haloperidol in the treatment of first-episode psychosis
74. A selective review of recent North American long-term followup studies of schizophrenia
75. Early detection and intervention in schizophrenia: Research
76. Duration of untreated psychosis in first-episode schizophrenia: Marker or determinant of course?
77. People at risk of schizophrenia and other psychoses: Comments on the Edinburgh High-Risk Study
78. EPPIC: An evolving system of early detection and optimal management
79. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia
80. Is schizophrenia a neurodevelopmental disorder?
81. Progression of cerebroventricular enlargement and the subtyping of schizophrenia
82. Proton magnetic resonance spectroscopy (1H MRS) of the hippocampal formation in schizophrenia: A pilot study
83. Information processing and attentional functioning in the developmental course of schizophrenic disorders
84. Information-processing abnormalities as neuropsychological vulnerability indicators for schizophrenia
85. Glutamate receptor dysfunction and schizophrenia
86. Conditioning a critical determinantof sensitization induced by psychomotor stimulants
87. Alterationsin brain high-energy phosphate and membrane phospholipid metabolism in first episode drug naive, schizophrenics
88. Asymmetries in hemispheric control of attention in schizophrenia
89. Progressive cortical change during adolescence in childhood-onset schizophrenia. A longitudinal magnetic resonance imaging study
90. Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis
91. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder
92. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder
93. Preventing severe mental illnesses - New prospects and ethical challenges
94. Psychopathology, executive (frontal) and general cognitive impairment in relation to duration of initially untreated versus subsequently treated psychosis in chronic schizophrenia
95. Proton magnetic resonance spectroscopy of the basal ganglia in patients with schizophrenia: A preliminary report
96. Deficits in sensory gating in schizophrenic patients and their relatives. Evidence obtained with auditory evoked responses
97. The use of a priori knowledge to quantify short echo in vivo 1H MR spectra
98. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy
99. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients
100. Course of treatment response in first-episode and chronic schizophrenia
101. Is the association between duration of untreated psychosis and outcome confounded? A two year follow-up study of first-admitted patients
102. Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonance spectroscopy
103. The neurodevelopmental basis of schizophrenia: Clinical clues from cerebro-craniofacial dysmorphogenesis, and the roots of a lifetime trajectory of disease
104. Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia
105. Codistribution of a sensory gating deficit and schizophrenia in multi-affected families
106. Prediction of adult-onset schizophrenia from childhood home movies of the patients
107. Immunoelectron microscopic study of glutamate inputs from the retrosplenial granular cortex to identified thalamocortical projection neurons in the anterior thalamus of the rat
108. Implications of normal brain development for the pathogenesis of schizophrenia
109. Increases in extracellular dopamine in the nucleus accumbens by cocaine are inversely related to basal levels: Effects of acute and repeated administration
110. Retinoid signaling distinguishes a subpopulation of olfactory receptor neurons in the developing and adult mouse
111. Case-finding instruments for depression. Two questions are as good as many
112. Early intervention with neuroleptics may decrease the long-term morbidity of schizophrenia
113. Early intervention for schizophrenia: Can the course of the illness be altered?
114. Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: A re-analysis of the Camarillo State Hospital data
115. Functional magnetic resonance imaging of schizophrenic patients and comparison subjects during word production